Back to All

Diaceutics (DxRx) and RxMx announce a new strategic partnership

18 November, 2021

Diaceutics (DxRx) and RxMx are pleased to announce a new strategic partnership with the shared goal to increase patients’ access to innovative therapies. Combining Diaceutics’ DXRX – The Diagnostic Network® platform and expanding, global lab network with the RxMx Chameleon platform, this partnership will provide a seamless solution to support pharmaceutical companies and healthcare systems.

RxMx and Diaceutics will bring together all the stakeholders in the patient journey into a dynamic, digital ecosystem. This will result in patients having an increased likelihood of receiving the right therapy at the right time, therefore improving patients’ outcomes. The two companies will also work together to explore new opportunities that would be best served by a combined effort.

Peter Keeling, CEO and Founder of Diaceutics PLC, commented: “We are delighted to have RxMx join the global DXRX partnership network which enables the launch of Precision Medicine diagnostics through our DXRX platform and growing global lab network.”

George Hunnewell, CEO of RxMx, remarked: "We’re thrilled to be partnering with Diaceutics to create a more comprehensive solution beginning with sourcing lab tests all the way through to monitoring patients’ therapy results on our Chameleon platform. Exciting days are ahead."

About Diaceutics
At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with a solution for the launch of Precision Medicine diagnostics enabled by DXRX - The Diagnostic Network®. DXRX is the world's first diagnostic commercialization platform for Precision Medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.

About RxMx
RxMx is an innovative digital health company that creates genuine efficiencies by connecting and automating the delivery of cutting-edge therapies through our doctor designed platform. Our technology connects patients, doctors, labs and other vendors, creating real-time integration and visibility across the patient journey, speeding up time to therapy and improving patient safety. We create unrivaled, real-time insights from complex program data, including automated clinical interpretation of lab results.

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.

Public Relations & Investor Relations advisers

Alma PR
71-73 Carter Lane

Tel: +44 (0)20 3405 0205 or [email protected]

Caroline Forde
Robyn Fisher
Kieran Breheny